Stephens & Co. Reiterates Equal-Weight on Insight Molecular, Maintains $4 Price Target
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Stephens & Co. analyst Mason Carrico reiterates Insight Molecular (NASDAQ:IMDX) with a Equal-Weight and maintains $4 price target.
Stephens & Co. analyst Mason Carrico reiterates Insight Molecular (NASDAQ:IMDX) with a Equal-Weight and maintains $4 price target.
